

Outcome good at one year for majority of PIMS-TS patients

August 31 2021



(HealthDay)—A majority of patients with pediatric inflammatory

multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 (PIMS-TS) have good medium- and long-term outcomes, according to a research letter published online Aug. 30 in *JAMA Pediatrics*.

Patrick Davies, from the Nottingham University Hospitals NHS Trust in the United Kingdom, and colleagues collected follow-up data to examine one-year outcomes in 68 children who received [critical care](#) for PIMS-TS or multisystem inflammatory [syndrome](#) and were part of the surviving cohort.

The researchers note there were no deaths and two patients (3 percent) had critical care readmission, which was unrelated to complications of PIMS-TS or immunomodulatory therapy. When patients were tested more than 50 days postadmission, only 3 percent of test results for C-reactive protein, 3 percent for D-dimer, and 2 percent for troponin were abnormal. Fourteen of 19 patients who presented with aneurysms had resolution; nine of 10 who presented with subjectively bright coronary arteries had resolution. By day 74, all those who presented with impaired function on echocardiography without aneurysm recovered. Aneurysmal changes were seen for all six patients with ongoing echocardiographic abnormalities. These patients had increased median C-reactive protein level at presentation, increased lymphocyte count, and elevated platelet count.

"Although our data identify a group of patients with a risk of significant long-term morbidity, it is reassuring that the majority of patients had good outcomes with no significant medium- or long-term sequelae," the authors write.

More information: [Abstract/Full Text](#)

Citation: Outcome good at one year for majority of PIMS-TS patients (2021, August 31)
retrieved 5 May 2024 from

<https://medicalxpress.com/news/2021-08-outcome-good-year-majority-pims-ts.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.